Annual Report

Overview

The report describes a strong 2020 operating recovery driven by quadrivalent influenza vaccine sales, with consolidated revenue of NT$1,869,147 thousand and profit before tax of NT$1,197,264 thousand. It also covers COVID-19 vaccine research and development, expansion of filling and cell-culture capacity, and a group workforce of approximately 503 employees. The company reports climate-risk integration into operational risk management, energy-saving and waste-reduction initiatives, and workplace safety systems. It had not yet compiled a separate CSR report.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2020
Period: Ends 31 December 2020
Publication date: 31 May 2021
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

Other

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services